SEC Form 4 · accession 0001179110-17-005555
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
A Robert D Bailey
Officer — Chief Legal Officer & Corp Sec
Period of report
Apr 3, 2017
Accepted (ET)
Apr 4, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2 | Apr 3, 2017 | A | 5,890 | $237.68 | A | 18,103 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022.
- F2Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.